Format
Sort by
Items per page

Send to

Choose Destination

Links from PubMed

Items: 1 to 20 of 47

1.

Distinct clinico-immunological profile of patients infected with human papilloma virus genotypes 6 and 11.

Singh M, Thakral D, Kar HK, Rishi N, Sharma PK, Mitra DK.

Virusdisease. 2017 Jun;28(2):200-204. doi: 10.1007/s13337-017-0370-z. Epub 2017 May 20.

PMID:
28770246
2.

Human papillomavirus vaccination: the population impact.

Lee LY, Garland SM.

F1000Res. 2017 Jun 12;6:866. doi: 10.12688/f1000research.10691.1. eCollection 2017. Review.

3.

Rates and determinants of incidence and clearance of cervical HPV genotypes among HIV-seropositive women in Pune, India.

Mane A, Sahasrabuddhe VV, Nirmalkar A, Risbud AR, Sahay S, Bhosale RA, Vermund SH, Mehendale SM.

J Clin Virol. 2017 Mar;88:26-32. doi: 10.1016/j.jcv.2016.10.013. Epub 2016 Oct 28.

PMID:
28152432
4.

The incidence, clearance and persistence of non-cervical human papillomavirus infections: a systematic review of the literature.

Taylor S, Bunge E, Bakker M, Castellsagué X.

BMC Infect Dis. 2016 Jun 14;16:293. doi: 10.1186/s12879-016-1633-9. Review.

5.

T cell ignorance is bliss: T cells are not tolerized by Langerhans cells presenting human papillomavirus antigens in the absence of costimulation.

Woodham AW, Yan L, Skeate JG, van der Veen D, Brand HH, Wong MK, Da Silva DM, Kast WM.

Papillomavirus Res. 2016 Dec;2:21-30.

6.

Human papillomavirus-exposed Langerhans cells are activated by stabilized Poly-I:C.

Da Silva DM, Woodham AW, Rijkee LK, Skeate JG, Taylor JR, Koopman ME, Brand HE, Wong MK, McKee GM, Salazar AM, Kast WM.

Papillomavirus Res. 2015 Dec 1;1:12-21. doi: 10.1016/j.pvr.2015.05.001.

7.

Immunostimulatory Activity of the Cytokine-Based Biologic, IRX-2, on Human Papillomavirus-Exposed Langerhans Cells.

Da Silva DM, Woodham AW, Naylor PH, Egan JE, Berinstein NL, Kast WM.

J Interferon Cytokine Res. 2016 May;36(5):291-301. doi: 10.1089/jir.2015.0115. Epub 2015 Dec 10.

8.

Human papillomavirus prevalence in South African women and men according to age and human immunodeficiency virus status.

Mbulawa ZZ, Coetzee D, Williamson AL.

BMC Infect Dis. 2015 Oct 26;15:459. doi: 10.1186/s12879-015-1181-8.

9.

Cervical HPV natural history among young Western Cape, South African women: The randomized control EVRI Trial.

Sudenga SL, Torres BN, Botha MH, Zeier M, Abrahamsen ME, Glashoff RH, Engelbrecht S, Schim Van der Loeff MF, Van der Laan LE, Kipping S, Taylor D, Giuliano AR.

J Infect. 2016 Jan;72(1):60-9. doi: 10.1016/j.jinf.2015.10.001. Epub 2015 Oct 19.

10.

Langerhans cells from women with cervical precancerous lesions become functionally responsive against human papillomavirus after activation with stabilized Poly-I:C.

Da Silva DM, Woodham AW, Skeate JG, Rijkee LK, Taylor JR, Brand HE, Muderspach LI, Roman LD, Yessaian AA, Pham HQ, Matsuo K, Lin YG, McKee GM, Salazar AM, Kast WM.

Clin Immunol. 2015 Dec;161(2):197-208. doi: 10.1016/j.clim.2015.09.003. Epub 2015 Sep 8.

11.

Papillomaviruses: Viral evolution, cancer and evolutionary medicine.

Bravo IG, Félez-Sánchez M.

Evol Med Public Health. 2015 Jan 28;2015(1):32-51. doi: 10.1093/emph/eov003. Review.

12.

Disparity in the persistence of high-risk human papillomavirus genotypes between African American and European American women of college age.

Banister CE, Messersmith AR, Cai B, Spiryda LB, Glover SH, Pirisi L, Creek KE.

J Infect Dis. 2015 Jan 1;211(1):100-8. doi: 10.1093/infdis/jiu394. Epub 2014 Jul 15.

13.

Prevalence of human papillomavirus in adolescent girls before reported sexual debut.

Houlihan CF, de Sanjosé S, Baisley K, Changalucha J, Ross DA, Kapiga S, Godinez JM, Bozicevic I, Hayes RJ, Watson-Jones D.

J Infect Dis. 2014 Sep 15;210(6):837-45. doi: 10.1093/infdis/jiu202. Epub 2014 Apr 16.

14.

Determinants of prevalent human papillomavirus in recently formed heterosexual partnerships: a dyadic-level analysis.

Burchell AN, Rodrigues A, Moravan V, Tellier PP, Hanley J, Coutlée F, Franco EL.

J Infect Dis. 2014 Sep 15;210(6):846-52. doi: 10.1093/infdis/jiu200. Epub 2014 Mar 27.

15.

Suppression of Langerhans cell activation is conserved amongst human papillomavirus α and β genotypes, but not a µ genotype.

Da Silva DM, Movius CA, Raff AB, Brand HE, Skeate JG, Wong MK, Kast WM.

Virology. 2014 Mar;452-453:279-86. doi: 10.1016/j.virol.2014.01.031. Epub 2014 Feb 17.

16.

Substantial increase in the frequency of circulating CD4+NKG2D+ T cells in patients with cervical intraepithelial neoplasia grade 1.

Garcia-Chagollan M, Jave-Suarez LF, Haramati J, Sanchez-Hernandez PE, Aguilar-Lemarroy A, Bueno-Topete MR, Pereira-Suarez AL, Fafutis-Morris M, Cid-Arregui A, del Toro-Arreola S.

J Biomed Sci. 2013 Aug 16;20:60. doi: 10.1186/1423-0127-20-60.

17.

HPV prevalence at enrollment and baseline results from the Carolina Women's Care Study, a longitudinal study of HPV persistence in women of college age.

Banister CE, Messersmith AR, Chakraborty H, Wang Y, Spiryda LB, Glover SH, Pirisi L, Creek KE.

Int J Womens Health. 2013 Jul 2;5:379-88. doi: 10.2147/IJWH.S45590. Print 2013.

18.

A prospective study of absolute risk and determinants of human papillomavirus incidence among young women in Costa Rica.

Clarke M, Schiffman M, Wacholder S, Rodriguez AC, Hildesheim A, Quint W; Costa Rican Vaccine Trial Group.

BMC Infect Dis. 2013 Jul 8;13:308. doi: 10.1186/1471-2334-13-308.

19.

The association of HPV-16 seropositivity and natural immunity to reinfection: insights from compartmental models.

Korostil IA, Garland SM, Law MG, Regan DG.

BMC Infect Dis. 2013 Feb 13;13:83. doi: 10.1186/1471-2334-13-83.

20.

Human papillomavirus in older women: new infection or reactivation?

Brown DR, Weaver B.

J Infect Dis. 2013 Jan 15;207(2):211-2. doi: 10.1093/infdis/jis662. Epub 2012 Dec 12. No abstract available.

Supplemental Content

Support Center